February 21, 2026
Headlines

Novo Nordisk’s Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial

Sumain Faisal01 mins

Novo Nordisk’s REDEFINE 2 trial shows CagriSema led to significant weight loss in patients with obesity and type 2 diabetes. Regulatory filing is planned for 2026.

read more

Leave a Reply

Your email address will not be published. Required fields are marked *

Related News